What is the difference between Semaglutide and Tirzepatide?

What is the difference between Semaglutide and Tirzepatide?

This is a common question from our patients at our medical weight loss clinic. First let me clear up the common confusion and misunderstanding around the names of these powerful new medications: semaglutide, developed by NovoNordisk, is known as Ozempic (used to treat type 2 diabetes) and Wegovy (used for weight loss). Tirzepatide, developed by Eli Lilly, is known as Mounjaro (for type 2 diabetes) and Zepbound (for weight loss). Both medications are commonly referred to as “weight loss injections” on social media. At Sound Medical Weight Loss we use both a lot! After a thorough medical intake, insurance coverage, potential out-of-pocket cost, side effects, and your personal weight loss goals, you can rest assured, that our expertly trained providers will help you choose the best weight loss medication for you. New research has compared these two popular weight-loss medications, and the results are exciting! Tirzepatide, which works on two hunger-related pathways, has shown to help people lose more weight than semaglutide, which targets just one hunger related pathway. In a large study of over 18,000 people, more patients using tirzepatide hit significant weight-loss goals such as 5%, 10%, or even 15% of their total body weight within a year. On average, tirzepatide users lost about 7% more weight than those on semaglutide by the end of 12 months. When prescribed by our highly experienced providers, both medications have excellent results. And both medications have similar side effects, like nausea, which can be managed with our knowledgeable medical team. These medications are game changers for people looking for effective ways to manage their weight. But stay tuned! These medications are being studied in the treatment of many other serious health conditions, such as heart failure and endocrine disorders. As new data emerges on these powerful medications, we will keep you up to date on the latest research.

Read the published article here: https://www.medrxiv.org/content/10.1101/2023.11.21.23298775v1

https://view.mc.lilly.com/?qs=125b21c9729ab030a3f98d69dba984638689b9f2bc1a61d4b7a13f1b5e61749ff21c35280221cd2f0c31ecf3f047b3bb7cc9477fafdc4be0a0699174433d44665a102138b108ab4c0cad0dc21cdc7292